Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$295952.0.

  • Outlook Therapeutics' Change in Accured Expenses fell 29247.16% to -$295952.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 1893.02%. This contributed to the annual value of $1.7 million for FY2025, which is 24779.29% up from last year.
  • Per Outlook Therapeutics' latest filing, its Change in Accured Expenses stood at -$295952.0 for Q4 2025, which was down 29247.16% from $354702.0 recorded in Q3 2025.
  • Outlook Therapeutics' 5-year Change in Accured Expenses high stood at $2.2 million for Q2 2025, and its period low was -$994707.0 during Q1 2025.